Loading the session
Loading the session
Loading instrument
$1.27
−0.78%DelayedDelayed 15 minutes · Source: ViewTrade · 6 Nov 2026, 16:21 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $1.28 on 5 Nov 2026: 69.7% below the 52-week high of $4.23 (6 May 2026) and 8.5% above the low of $1.18 (5 Nov 2026).
Daily price bars, split-adjusted · as of 5 Nov 2026
1 month: −35.0% (SPY −5.7%, XLV +9.5%). 3 months: −53.6% (SPY −4.6%, XLV +12.4%). 1 year: −51.0% (SPY +8.2%, XLV +26.9%). Price change to the 5 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CABA, SPY and XLV · as of 5 Nov 2026
39.3M shares were sold short at the 15 Oct 2026 settlement, 23.2% of the 169.5M shares outstanding; covering them would take 7.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 5 Nov 2026 close of $1.28 was 40.7% below its 50-day average ($2.16) and 54.9% below its 200-day average ($2.84). It has closed below the 200-day for 42 sessions, since 9 Sep 2026. The 50-day average crossed below the 200-day on 15 Sep 2026, 37 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 5 Nov 2026
The 14-session relative strength index closed at 29.7 on 5 Nov 2026, its 1st session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 5 Nov 2026
Price return, split-adjusted
At the 5 Nov 2026 close
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
October 31, 2025
+46.15%October 20, 2022
+50.77%December 14, 2021
−73.14%